Sign In
Buy DCTH
$10.33
-0.200 (-1.90%)
At Close: Jun 03, 2026
Delcath Stock Moves Higher After Hepzato Achieves ORR Of 29.2% Beating Prespecified Threshold In Eye Cancer Study
08:06am, Wednesday, 31'st Mar 2021
Delcath Systems Inc (NASDAQ: DCTH) has announced top-line preliminary results from the Phase 3 FOCUS trial of Hepzato Kit (melphalan hydrochloride for injection/hepatic delivery system) in patient
NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today rep
Delcath Systems, Inc. Announces Positive Preliminary Results from Phase 3 FOCUS Trial of HEPZATO in Patients with Metastatic Ocular Melanoma
07:30am, Wednesday, 31'st Mar 2021
Based on Preliminary Data, FOCUS Trial Achieves Prespecified Success Threshold
Delcath Systems Schedules Conference Call to Report 2020 Fourth Quarter Financial Results
04:01pm, Wednesday, 24'th Mar 2021
NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, ann
Delcath Systems: Cancer-Treatment Device Company With Upcoming Phase 3 Readout
03:40am, Tuesday, 09'th Feb 2021
Delcath Systems develops drug/device combos to treat liver cancers. The company's stock is underappreciated due to past clinical failures and a de-listing despite promising clinical data.
Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference
10:56am, Monday, 11'th Jan 2021
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,
Delcath Systems Announces Completion of Underwritten Public Offering
10:31am, Friday, 11'th Dec 2020
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today
Delcath Systems Announces Proposed Public Offering of Common Stock
04:01pm, Tuesday, 08'th Dec 2020
NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today
Kevin Muir Joins Delcath Systems, Inc. as VP, Commercial Operations
07:30am, Monday, 07'th Dec 2020
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today anno
Delcath Systems, Inc. (DCTH) CEO Gerard Michel on Q3 2020 Results - Earnings Call Transcript
01:29pm, Wednesday, 11'th Nov 2020
Delcath Systems, Inc. (DCTH) CEO Gerard Michel on Q3 2020 Results - Earnings Call Transcript
Delcath Systems, Inc. to Participate in Oppenheimer Fall MedTech Summit on Thursday, November 12, 2020
04:01pm, Monday, 02'nd Nov 2020
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announ
Delcath Schedules Conference Call to Report 2020 Third Quarter Financial Results
09:00am, Monday, 02'nd Nov 2020
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announ
Overall Response Rate of 72% observed in patients with metastases confined to the liver Overall Response Rate of 72% observed in patients with metastases confined to the liver
Zacks Investment Research Upgrades Delcath Systems (OTCMKTS:DCTH) to “Hold”
05:46am, Thursday, 15'th Oct 2020
Zacks Investment Research upgraded shares of Delcath Systems (OTCMKTS:DCTH) from a sell rating to a hold rating in a report issued on Wednesday morning, Zacks.com reports. According to Zacks, “Delca
Delcath: Peek Of Early Data Of FOCUS Trial Shows Vastly Improved Safety Profile Of Chemosat (NASDAQ:DCTH)
10:14pm, Friday, 25'th Sep 2020
Safety data of early part of FOCUS trial have been publicly disseminated. Early data of FOCUS trial show a vastly improved safety profile of Chemosat.
